# US 2025/0152659 A1 · Method for preventing or treating parkinson's disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152659 A1
- Document ID: US20250152659A1
- Status: Published application
- Kind: A1
- Application number: 19/026,254
- Filed: 2025-01-16
- Published: 2025-05-15
- Earliest claimed: 2022-09-16
- Assignees: Suzhou Mingren Pharmaceutical Biotechnology Co., Ltd.
- Applicants: Suzhou Mingren Pharmaceutical Biotechnology Co., Ltd.
- Inventors: Jianwei ZHOU
- Web page: https://patentgrep.com/patent/US20250152659A1

## CPC

- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61P 25/16: Anti-Parkinson drugs
- C07K 2319/01: containing a localisation/targetting motif
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A method for preventing or treating Parkinson's disease including administering a patient in need thereof a pharmaceutical composition including a polypeptide, the peptide having an amino acid sequence I or II: I: FPGSDRF (SEQ ID NO: 1)-Z; II: X-FPGSDRF (SEQ ID NO: 1)-Z; S represents phosphorylated serine; X and Z independently represents an amino acid or an amino acid sequence; X is selected from F, (R)9 (SEQ ID NO: 2), (R)9-F (SEQ ID NO: 3), 6-aminohexanoic acid, 6-aminohexanoic acid-F, 6-aminohexanoic acid-(R)9 (SEQ ID NO: 2), 6-aminohexanoic acid-(R)9-F (SEQ ID NO: 3); and Z is selected from (G)n-RGD or A-(G)n-RGD (SEQ ID NO: 4), where n is an integer greater than or equal to 0, in the range of 0-10.

## Claims

### Claim 1

A method for preventing or treating Parkinson's disease comprising administering a patient in need thereof a pharmaceutical composition comprising a polypeptide, the peptide having an amino acid sequence I or II:
I: FPGSDRF (SEQ ID NO: 1)-Z;
II: X-FPGSDRF (SEQ ID NO: 1)-Z;
wherein:
S represents phosphorylated serine;
X and Z independently represents an amino acid or an amino acid sequence;
X is selected from F, (R)9 (SEQ ID NO: 2), (R)9-F (SEQ ID NO: 3), 6-aminohexanoic acid, 6-aminohexanoic acid-F, 6-aminohexanoic acid-(R)9 (SEQ ID NO: 2), 6-aminohexanoic acid-(R)9-F (SEQ ID NO: 3); and
Z is selected from (G)n-RGD or A-(G)n-RGD (SEQ ID NO: 4), where n is an integer greater than or equal to 0, in the range of 0-10.

### Claim 2 (depends on 1)

The method of claim 1, wherein a symptom of the Parkinson's disease is excessive activation or proliferation of astrocytes or microglia in brain tissue.

### Claim 3 (depends on 1)

The method of claim 1, wherein a symptom of the Parkinson's disease is degeneration or loss of dopamine neurons in brain tissue.

### Claim 4 (depends on 1)

The method of claim 1, wherein a symptom of the Parkinson's disease is weakened vitality of hippocampal neurons or glial cells due to cytotoxic effects.

### Claim 5 (depends on 1)

The method of claim 1, wherein a symptom of the Parkinson's disease is increased expression of inflammasomes and increased apoptosis in hippocampal neurons or glial cells.

### Claim 6 (depends on 1)

The method of claim 1, wherein a symptom of the Parkinson's disease is increased membrane potential and elevated intracellular levels of reactive oxygen due to damage of cellular mitochondria in hippocampal neuronal cells or neuroglial cells.

### Claim 7 (depends on 1)

The method of claim 1, wherein the polypeptide comprises an acetylated N-terminal and an amidated C-terminal.

### Claim 8 (depends on 1)

The method of claim 1, wherein the polypeptide has an amino acid sequence of FPGSDRF-RGD, and serine (S) of the amino acid sequence of FPGSDRF-RGD is phosphorylated.

### Claim 9 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.
